Millennium Management’s AbCellera Biologics ABCL Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q4
– Sell
-250,000
Closed -$1.15M – 6007
2023
Q3
$1.15M Buy
+250,000
New +$1.52M ﹤0.01% 4081
2023
Q2
– Sell
-300,000
Closed -$2.26M – 6041
2023
Q1
$2.26M Buy
300,000
+139,100
+86% +$1.26M ﹤0.01% 3320
2022
Q4
$1.63M Sell
160,900
-139,100
-46% -$1.61M ﹤0.01% 3731
2022
Q3
$2.97M Buy
+300,000
New +$3.29M ﹤0.01% 3401

Other funds holding ABCL

Millennium Management's ABCL Position: Q3 2026 in Review

Millennium Management increased its AbCellera Biologics (ABCL) stake by 293% in Q3 2026, buying an estimated $14.4M and bringing the position to 2,038,187 shares worth $29.7M. The position accounts for 0.01% of the portfolio, ranked #1301.

Millennium Management first reported a position in ABCL in Q4 2020 and has held it in 24 quarters since. The position peaked at $31.5M in Q2 2022. 164 funds tracked by Wall St. Rank hold ABCL as of Q3 2026.

  • Millennium Management held 2,038,187 shares of AbCellera Biologics worth $29.7M as of Q3 2026.
  • Millennium Management bought 1,519,616 AbCellera Biologics shares in Q3 2026, an estimated $14.4M.
  • AbCellera Biologics made up 0.01% of Millennium Management's portfolio in Q3 2026, its #1301 holding.
  • Millennium Management first reported a position in AbCellera Biologics in Q4 2020 and has held it in 24 quarters since.
  • Millennium Management's AbCellera Biologics position peaked at $31.5M in Q2 2022.
  • 164 funds tracked by Wall St. Rank held AbCellera Biologics as of Q3 2026.

Based on Millennium Management's 13F filing for Q3 2026, filed 16 Nov 2026.